Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2022

View Archived Issues

LONP1 targeting sensitizes therapy-resistant tumor cells to sorafenib

VesiVax Af3/9 vaccine protects against invasive pulmonary aspergillosis

Renovacor to advance AAV gene therapy program for arrhythmogenic cardiomyopathy

Beijing Innocare Medical Technology patents JAK inhibitors

MJFF grant supports evaluation of EpicentRx's NLRP3 inflammasome inhibitor for Parkinson's

Shanghai Visonpharma discloses new GTPase KRAS inhibitors

Galapagos NV presents new DDR inhibitors

Chinese researchers synthesize new GTPase KRAS inhibitors

Royal College of Surgeons in Ireland discloses HDAC6 inhibitors

Co-targeting MAPK and YAP-TEAD signaling as therapeutic strategy in melanoma

Targeting IL-33 release may be an approach for treating HCC

"Master sites" trigger cascade of tau phosphorylation in Alzheimer's disease

Novel genetic loci found for venous thromboembolism

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...